Iomed
Vista · Founded 1974
About Iomed
IOMED, Inc.develops, manufactures and commercializes controllable drug delivery systems using iontophoretic technology. Iontophoresis is a non-invasive method of enhancing and controlling the transport of water-soluble ionic drugs into and through the skin using a low level electrical current. The Company's proprietary iontophoretic drug delivery systems allow rapid onset and cessation of therapeutic action, as well as programmable dose control. The systems enable caregivers and patients to control the onset of drug effectiveness and maintain, reduce or cease drug administration once a desired therapeutic effect is observed. The programming feature also enables caregivers to customize dosing patterns to meet each patient's specific needs. The Company is developing systems designed to enable patient monitoring and control. The flexibility of the Company's proprietary systems provides therapeutic control not possible with many alternative drug delivery methods, including oral tablets and capsules, injections, inhalants and passive transdermal patches. The Company's systems may also increase bioavailability, safety and patient comfort.
Company Facts
- Founded: 1974
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Funding stage: M&A
- Ticker: nysemkt:IOX
Canonical: https://fsome.com/organization/iomed-2005288 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.